-
1
-
-
0346729968
-
Ceramide Content Is Increased in Skeletal Muscle from Obese Insulin-Resistant Humans
-
DOI 10.2337/diabetes.53.1.25
-
JM Adams T Pratipanawatr R Berria, et al.. 2004 Ceramide content is increased in skeletal muscle from obese insulin-resistant humans Diabetes 53 25 31 10.2337/diabetes.53.1.25 1:CAS:528:DC%2BD2cXitlagtQ%3D%3D 14693694 (Pubitemid 38044694)
-
(2004)
Diabetes
, vol.53
, Issue.1
, pp. 25-31
-
-
Adams II, J.M.1
Pratipanawatr, T.2
Berria, R.3
Wang, E.4
DeFronzo, R.A.5
Sullards, M.C.6
Mandarino, L.J.7
-
2
-
-
34848921862
-
Increased skeletal muscle ceramide level in men at risk of developing type 2 diabetes
-
DOI 10.1007/s00125-007-0781-2
-
M Straczkowski I Kowalska M Baranowski, et al.. 2007 Increased skeletal muscle ceramide level in men at risk of developing type 2 diabetes Diabetologia 50 2366 2373 10.1007/s00125-007-0781-2 1:CAS:528:DC%2BD2sXhtFSlsL3M 17724577 (Pubitemid 47512392)
-
(2007)
Diabetologia
, vol.50
, Issue.11
, pp. 2366-2373
-
-
Straczkowski, M.1
Kowalska, I.2
Baranowski, M.3
Nikolajuk, A.4
Otziomek, E.5
Zabielski, P.6
Adamska, A.7
Blachnio, A.8
Gorski, J.9
Gorska, M.10
-
3
-
-
2342621476
-
Relationship between Insulin Sensitivity and Sphingomyelin Signaling Pathway in Human Skeletal Muscle
-
DOI 10.2337/diabetes.53.5.1215
-
M Straczkowski I Kowalska A Nikolajuk, et al.. 2004 Relationship between insulin sensitivity and sphingomyelin signaling pathway in human skeletal muscle Diabetes 53 1215 1221 10.2337/diabetes.53.5.1215 1:CAS:528:DC%2BD2cXjslKiu70%3D 15111489 (Pubitemid 38569006)
-
(2004)
Diabetes
, vol.53
, Issue.5
, pp. 1215-1221
-
-
Straczkowski, M.1
Kowalska, I.2
Nikolajuk, A.3
Dzienis-Straczkowska, S.4
Kinalska, I.5
Baranowski, M.6
Zendzian-Piotrowska, M.7
Brzezinska, Z.8
Gorski, J.9
-
4
-
-
44749085396
-
Human skeletal muscle ceramide content is not a major factor in muscle insulin sensitivity
-
10.1007/s00125-008-1014-z 1:CAS:528:DC%2BD1cXmslWhtbk%3D 18458871
-
M Skovbro M Baranowski C Skov-Jensen, et al.. 2008 Human skeletal muscle ceramide content is not a major factor in muscle insulin sensitivity Diabetologia 51 1253 1260 10.1007/s00125-008-1014-z 1:CAS:528: DC%2BD1cXmslWhtbk%3D 18458871
-
(2008)
Diabetologia
, vol.51
, pp. 1253-1260
-
-
Skovbro, M.1
Baranowski, M.2
Skov-Jensen, C.3
-
5
-
-
31644443192
-
Ceramides in insulin resistance and lipotoxicity
-
DOI 10.1016/j.plipres.2005.11.002, PII S0163782705000500
-
SA Summers 2006 Ceramides in insulin resistance and lipotoxicity Prog Lipid Res 45 42 72 10.1016/j.plipres.2005.11.002 1:CAS:528:DC%2BD28XhtV2ksbg%3D 16445986 (Pubitemid 43170804)
-
(2006)
Progress in Lipid Research
, vol.45
, Issue.1
, pp. 42-72
-
-
Summers, S.A.1
-
6
-
-
45149106053
-
Sphingolipids, insulin resistance, and metabolic disease: New insights from in vivo manipulation of sphingolipid metabolism
-
DOI 10.1210/er.2007-0025
-
WL Holland SA Summers 2008 Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism Endocr Rev 29 381 402 10.1210/er.2007-0025 1:CAS:528: DC%2BD1cXosVCqu7w%3D 18451260 (Pubitemid 351831506)
-
(2008)
Endocrine Reviews
, vol.29
, Issue.4
, pp. 381-402
-
-
Holland, W.L.1
Summers, S.A.2
-
7
-
-
67649231047
-
The role of skeletal muscle sphingolipids in the development of insulin resistance
-
10.1900/RDS.2008.5.13 18548166
-
M Straczkowski I Kowalska 2008 The role of skeletal muscle sphingolipids in the development of insulin resistance Rev Diabet Stud 5 13 24 10.1900/RDS.2008.5.13 18548166
-
(2008)
Rev Diabet Stud
, vol.5
, pp. 13-24
-
-
Straczkowski, M.1
Kowalska, I.2
-
8
-
-
34250303939
-
Key role for ceramides in mediating insulin resistance in human muscle cells
-
DOI 10.1074/jbc.M611157200
-
L Pickersgill GJ Litherland AS Greenberg M Walker SJ Yeaman 2007 Key role for ceramides in mediating insulin resistance in human muscle cells J Biol Chem 282 12583 12589 10.1074/jbc.M611157200 1:CAS:528:DC%2BD2sXksVSisro%3D 17337731 (Pubitemid 47100630)
-
(2007)
Journal of Biological Chemistry
, vol.282
, Issue.17
, pp. 12583-12589
-
-
Pickersgill, L.1
Litherland, G.J.2
Greenberg, A.S.3
Walker, M.4
Yeaman, S.J.5
-
9
-
-
33847332202
-
Inhibition of Ceramide Synthesis Ameliorates Glucocorticoid-, Saturated-Fat-, and Obesity-Induced Insulin Resistance
-
DOI 10.1016/j.cmet.2007.01.002, PII S1550413107000034
-
WL Holland JT Brozinick LP Wang, et al.. 2007 Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance Cell Metab 5 167 179 10.1016/j.cmet.2007.01.002 1:CAS:528:DC%2BD2sXjsF2qtL8%3D 17339025 (Pubitemid 46317299)
-
(2007)
Cell Metabolism
, vol.5
, Issue.3
, pp. 167-179
-
-
Holland, W.L.1
Brozinick, J.T.2
Wang, L.-P.3
Hawkins, E.D.4
Sargent, K.M.5
Liu, Y.6
Narra, K.7
Hoehn, K.L.8
Knotts, T.A.9
Siesky, A.10
Nelson, D.H.11
Karathanasis, S.K.12
Fontenot, GregK.13
Birnbaum, M.J.14
Summers, S.A.15
-
10
-
-
70949101414
-
Link between plasma ceramides, inflammation and insulin resistance: Association with serum IL-6 concentration in patients with coronary heart disease
-
10.1007/s00125-009-1482-9 19669729
-
VD de Mello M Lankinen U Schwab, et al.. 2009 Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease Diabetologia 10.1007/s00125-009-1482-9 19669729
-
(2009)
Diabetologia
-
-
De Mello, V.D.1
Lankinen, M.2
Schwab, U.3
-
11
-
-
63249117466
-
Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance
-
10.2337/db08-1228 1:CAS:528:DC%2BD1MXhslersLY%3D 19008343
-
JM Haus SR Kashyap T Kasumov, et al.. 2009 Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance Diabetes 58 337 343 10.2337/db08-1228 1:CAS:528: DC%2BD1MXhslersLY%3D 19008343
-
(2009)
Diabetes
, vol.58
, pp. 337-343
-
-
Haus, J.M.1
Kashyap, S.R.2
Kasumov, T.3
-
12
-
-
34247170807
-
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
-
DOI 10.1056/NEJMoa065213
-
CM Larsen M Faulenbach A Vaag, et al.. 2007 Interleukin-1-receptor antagonist in type 2 diabetes mellitus N Engl J Med 356 1517 1526 10.1056/NEJMoa065213 1:CAS:528:DC%2BD2sXkt1Sjtr4%3D 17429083 (Pubitemid 46588416)
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.15
, pp. 1517-1526
-
-
Larsen, C.M.1
Faulenbach, M.2
Vaag, A.3
Volund, A.4
Ehses, J.A.5
Seifert, B.6
Mandrup-Poulsen, T.7
Donath, M.Y.8
-
13
-
-
43049099344
-
Novel biochemical risk factors for type 2 diabetes: Pathogenic insights or prediction possibilities?
-
10.1007/s00125-008-0954-7 1:CAS:528:DC%2BD1cXlt1Crsbw%3D 18392804
-
N Sattar SG Wannamethee NG Forouhi 2008 Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities? Diabetologia 51 926 940 10.1007/s00125-008-0954-7 1:CAS:528:DC%2BD1cXlt1Crsbw%3D 18392804
-
(2008)
Diabetologia
, vol.51
, pp. 926-940
-
-
Sattar, N.1
Wannamethee, S.G.2
Forouhi, N.G.3
|